

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Carton box (of 1 or 50 Syringes)}**

**CASE N°1:** *The text below corresponds to the cases where all the information of the package leaflet can not be conveyed on the outer packaging and the container (for example for multilingual packaging). Consequently a package leaflet is added (see the corresponding template).*

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

EQVALAN DUO, oral paste

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each g contains:

Ivermectin: 15.5 mg

Praziquantel: 77.5 mg

**3. PACKAGE SIZE**

1 syringe of 7.74 g

1 syringe of 9.68 g

1 syringe of 14.19 g

50 syringes of 7.74 g

50 syringes of 9.68 g

50 syringes of 14.19 g

**4. TARGET SPECIES**

Horses.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

Withdrawal periods:

Meat and offal: 30 days

Not authorised for use in animal producing milk for human consumption.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened, use within 2 years.

## **9. SPECIAL STORAGE PRECAUTIONS**

Store in the original container.  
Replace the cap after use.

## **10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

## **11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

## **13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Boehringer Ingelheim Animal Health UK Limited

## **14. MARKETING AUTHORISATION NUMBERS**

Vm 08327/5003

## **15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING WHERE THERE IS NO PACKAGE LEAFLET, i.e. Combined label and package leaflet {Carton box (1 or 50 syringes)}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

EQVALAN DUO, oral paste

**2. COMPOSITION**

Each g contains:

**Active substance:**

Ivermectin:	15.5 mg
Praziquantel:	77.5 mg

**Excipients:**

Titanium oxide (E171):	20 mg
Sunset yellow FCF (E110):	0.40 mg
Butylhydroxyanisole (E320):	0.20 mg

Smooth, homogeneous orange paste.

**3. PACKAGE SIZE**

1 syringe of 7.74 g  
1 syringe of 9.68 g  
1 syringe of 14.19 g

50 syringes of 7.74 g  
50 syringes of 9.68 g  
50 syringes of 14.19 g

**4. TARGET SPECIES**

Horses.

**5. INDICATIONS FOR USE**

**Indications for use**

For the treatment of mixed cestode and nematode or arthropod infestations in horses. The following parasites of horses are sensitive to the antiparasitic effects of the veterinary medicinal product:

**Adult Tapeworms:** *Anoplocephala perfoliata*, *Anoplocephala magna*

**Large strongyles:** *Strongylus vulgaris* (adults and arterial larval stages), *Strongylus edentatus* (adults and tissue larval stages), *Strongylus equinus* (adults), *Triodontophorus* spp. (adults), *Triodontophorus brevicauda*, *Triodontophorus serratus*, *Craterostomum acuticaudatum* (adults).

**Adult and immature (intraluminal fourth-stage larvae) of small strongyles or cyathostomes, including benzimidazole-resistant strains:** *Coronocyclus* spp.,

*Coronocyclus coronatus*, *Coronocyclus labiatus*, *Coronocyclus labratus*, *Cyathostomum* spp., *Cyathostomum catinatum*, *Cyathostomum pateratum*, *Cylicocyclus* spp., *Cylicocyclus ashworthi*, *Cylicocyclus elongates*, *Cylicocyclus insigne*, *Cylicocyclus leptostomum*, *Cylicocyclus nassatus*, *Cylicodontophorus* spp., *Cylicodontophorus bicornatus*, *Cylicostephanus* spp., *Cylicostephanus calicatus*, *Cylicostephanus goldi*, *Cylicostephanus longibursatus*, *Cylicostephanus minutes*, *Parapoteriostomum* spp., *Parapoteriostomum mettami*, *Petrovinema* spp., *Petrovinema poculatum*, *Poteriostomum* spp.,  
**Adult hairworms:** *Trichostrongylus axei*.

**Adult and immature (fourth stage Larvae) pinworms:** *Oxyuris equi*.

**Adult, third- and fourth-stage larvae of roundworms (ascarids):** *Parascaris equorum*. **Microfilariae of neck threadworms:** *Onchocerca* spp.

**Adult intestinal threadworms:** *Strongyloides westeri*.

**Adult large-mouth stomach worms:** *Habronema muscae*. Oral and, gastric stages of bots: *Gasterophilus* spp.

**Adult and immature (inhibited fourth stage larvae) lungworms:** *Dictyocaulus arnfieldi*.

## 6. CONTRAINDICATIONS

### Contraindications

The veterinary medicinal product has been formulated for use in horses only. Cats, Dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also turtles and tortoises may be adversely affected by the concentration of ivermectin in this veterinary medicinal product if they are allowed to ingest spilled paste or have access to used syringes.

## 7. SPECIAL WARNINGS

### Special warnings

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of body weight, misadministration of the veterinary medicinal product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Resistance to macrocyclic lactones (which includes ivermectin) has been reported in *Parascaris equorum* in horses in a number of countries, including the EU. Therefore, the use of this veterinary medicinal product should be based on local (regional, farm) epidemiological information about susceptibility of gastro-intestinal nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

Special precautions for safe use in the target species:

Safety studies were not conducted in foals younger than 2 months of age, or in stallions, the use of the veterinary medicinal product is not recommended in these categories of animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after use.

Do not smoke, drink or eat while handling the veterinary medicinal product.

This veterinary medicinal product may cause skin and eye irritation. Therefore, the user should avoid contact of the veterinary medicinal product with the skin and the eyes. In case of contact, rinse immediately with plenty of water.

In the case of accidental ingestion or eye irritation after contact seek medical advise immediately and show the package insert or the label to the physician.

Pregnancy and lactation:

Studies performed in laboratory animals showed no teratogenic or embryotoxic effect of either ivermectin or praziquantel at the recommended doses during therapy.

Ivermectin-Praziquantel combination can be used after the first three months of gestation and during lactation. In the absence of clinical data in early pregnancy the veterinary medicinal product can only be used in the first three months of gestation according to a risk benefit analysis by the veterinarian.

Overdose:

No undesirable effects related to treatment were observed in 2 months old horses treated with the veterinary medicinal product at up to three times the recommended dose and in adult horses treated at ten times the recommended dose.

Transient decreased food consumption, increased body temperature, salivation and impairment of vision were noticed in horses treated twice with an ivermectin oral paste or once with the veterinary medicinal product at ten times the recommended dose (i.e., 2 mg/kg b.w.). All changes disappeared within five days.

No antidote has been identified; however, symptomatic therapy may be beneficial.

## 8. ADVERSE EVENTS

### Adverse events

Horses:

**Rare (1 to 10 animals / 10,000 animals treated):** Oedema<sup>1</sup> and pruritis<sup>1</sup>

Inflammation of the mouth, lip and tongue (e.g., oedema, hypersalivation, erythema, tongue disorder and stomatitis)<sup>2</sup>.

**Very rare (<1 animal / 10,000 animals treated, including isolated reports):** Colic, loose stool<sup>3</sup>.

<sup>1</sup>Can occur in some horses with heavy infections of *Onchocerca* spp. microfilariae following the treatment; such reactions were assumed to be the result of the death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable.

<sup>2</sup>These reactions have been transitory in nature, appearing within 1 hour and abating within 24 to 48 hours following administration. In case of severe oral reactions symptomatic treatment is recommended.

<sup>3</sup>Mild, transient signs may be observed in cases of heavy infestations with tapeworms.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorization holder <or the local representative of the marketing authorization holder> using the contact details at the end of this leaflet, or via your national reporting system: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine> and [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **9. DOSAGE FOR EACH TARGET SPECIES, ROUTES AND METHOD OF ADMINISTRATION**

### **Dosage for each species, routes and method of administration**

Oral use.

#### Dosage:

The recommended dosage is 200 mcg/kg bw of ivermectin and 1 mg/kg bw of praziquantel corresponding to 1.29 g of paste per 100 kg bodyweight in a single administration.

Bodyweight and dosage should be accurately determined prior to treatment. For syringes intended to treat horses up to 600 kg and 1100 kg, calibrated markings are provided at 100 kg bodyweight intervals. For the syringe intended to treat horses up to 750 kg, calibrated markings are provided at 125 kg bodyweight intervals. The syringe should be adjusted to the calculated dosage by setting the ring on the appropriate place on the plunger.

Parasite control Program: Veterinary advice should be given on appropriate dosing programs and stock management to achieve adequate parasite control for both tapeworm and roundworm infestations.

## **10. ADVICE ON CORRECT ADMINISTRATION**

### **Advice on correct administration**

To ensure a correct dosage, body weight should be determined as accurately as possible.

While holding the plunger, turn the knurled ring on the plunger ¼ turn to the left and slide it so the stop ring is at the prescribed weight marking. Lock the ring in place by turning it ¼ turn to the right in order to bring the two arrows, the one visible on the ring and the one on the plunger rod, into alignment. Make sure the horse's mouth contains no feed. Remove the cover from the tip of the syringe. Insert the syringe tip into the horse's mouth at the interdental space and deposit the paste on the base of

the tongue. Immediately raise the horse's head for a few seconds after dosing and ensure that the paste is consumed.

## **11. WITHDRAWAL PERIODS**

### **Withdrawal periods**

Meat and offal: 30 days.

Not authorised for use in animal producing milk for human consumption.

## **12. SPECIAL STORAGE PRECAUTIONS**

### **Special storage precautions**

Keep out of the sight and reach of children.

Store in the original container.

Replace the cap after use.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

## **13. SPECIAL PRECAUTIONS FOR DISPOSAL**

### **Special precautions for disposal**

Medicines should not be disposed of via wastewater.

The veterinary medicinal product should not enter water course as ivermectin and praziquantel may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

## **14. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

### **Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **15. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 08327/5003

### **Pack sizes**

Carton box of 1 syringe for oral administration of 7.74g

Carton box of 1 syringe for oral administration of 9.68g

Carton box of 1 syringe for oral administration of 14.19g

Carton box of 50 syringes for oral administration of 7.74g

Carton box of 50 syringes for oral administration of 9.68g

Carton box of 50 syringes for oral administration of 14.19g

Not all pack sizes may be marketed.

## **16. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **17. CONTACT DETAILS**

### **Contact details**

Marketing authorisation holder and contact details to report suspected adverse reactions:

Boehringer Ingelheim Animal Health UK Limited  
Ellesfield Avenue  
Bracknell  
Berkshire  
RG12 8YS  
UK

Manufacturer responsible for batch release:

Boehringer Ingelheim Animal Health France SCS  
4, Chemin du Calquet  
31000 Toulouse  
France

## **18. OTHER INFORMATION**

### **Environmental properties**

EXTREMELY DANGEROUS FOR FISH AND AQUATIC LIFE.

POM-VPS

## **19. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

## **20. EXPIRY DATE**

Exp: {mm/yyyy}

Once opened, use within 2 years

## **21. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING  
UNITS {Syringe}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

EQVALAN DUO



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Ivermectin 15.5 mg/g  
Praziquantel 77.5 mg/g

7.74 g  
9.68 g  
14.19 g

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}  
Once opened use by....

**PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

**PACKAGE LEAFLET**

*The leaflet described below applies to Case N°1 where a package leaflet is added in the packaging.*

*In Case N°2 no leaflet is needed.*

**1. Name of the veterinary medicinal product**

EQVALAN DUO, oral paste

**2. Composition**

Each g contains:

**Active substances:**

Ivermectin.....15.5 mg  
Praziquantel.....77.5 mg

**Excipients:**

Titanium dioxide (E171)..... 20 mg  
Sunset Yellow (E110)..... 0.40 mg  
Butylhydroxyanisole (E320)..... 0.20 mg

Smooth, homogeneous orange paste.

**3. Target species**

Horses.

**4. Indications for use**

For the treatment of mixed cestode and nematode or arthropod infestations in horses. The following parasites of horses are sensitive to the antiparasitic effects of the veterinary medicinal product:

**Adult Tapeworms:** *Anoplocephala perfoliata*, *Anoplocephala magna*

**Large strongyles:** *Strongylus vulgaris* (adults and arterial larval stages), *Strongylus edentatus* (adults and tissue larval stages), *Strongylus equinus* (adults), *Triodontophorus* spp. (adults), *Triodontophorus brevicauda*, *Triodontophorus serratus*, *Craterostomum acuticaudatum* (adults).

**Adult and immature (intraluminal fourth-stage larvae) of small strongyles or cyathostomes, including benzimidazole-resistant strains:** *Coronocyclus* spp., *Coronocyclus coronatus*, *Coronocyclus labiatus*, *Coronocyclus labratus*, *Cyathostomum* spp., *Cyathostomum catinatum*, *Cyathostomum pateratum*, *Cylicocyclus* spp., *Cylicocyclus ashworthi*, *Cylicocyclus elongates*, *Cylicocyclus insigne*, *Cylicocyclus leptostomum*, *Cylicocyclus nassatus*, *Cylicodontophorus* spp., *Cylicodontophorus bicornatus*, *Cylicostephanus* spp., *Cylicostephanus calicatus*, *Cylicostephanus goldi*,

*Cylicostephanus longibursatus*, *Cylicostephanus minutes*, *Parapoteriostomum* spp.,  
*Parapoteriostomum mettami*, *Petrovinema* spp., *Petrovinema poculatum*,  
*Poteriostomum* spp.,

**Adult hairworms:** *Trichostrongylus axei*.

**Adult and immature (fourth stage Larvae) pinworms:** *Oxyuris equi*.

**Adult, third- and fourth-stage larvae of roundworms (ascarids):** *Parascaris equorum*. **Microfilariae of neck threadworms:** *Onchocerca* spp.

**Adult intestinal threadworms:** *Strongyloides westeri*.

**Adult large-mouth stomach worms:** *Habronema muscae*.

**Oral and, gastric stages of bots:** *Gasterophilus* spp.

**Adult and immature (inhibited fourth stage larvae) lungworms:** *Dictyocaulus arnfieldi*.

## 5. Contraindications

The veterinary medicinal product has been formulated for use in horses only. Cats, Dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also turtles and tortoises may be adversely affected by the concentration of ivermectin in this veterinary medicinal product if they are allowed to ingest spilled paste or have access to used syringes.

## 6. Special warnings

### Special warnings:

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of body weight, misadministration of the veterinary medicinal product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Resistance to macrocyclic lactones (which includes ivermectin) has been reported in *Parascaris equorum* in horses in a number of countries, including the EU. Therefore, the use of this veterinary medicinal product should be based on local (regional, farm) epidemiological information about susceptibility of gastro-intestinal nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

### Special precautions for safe use in the target species:

Safety studies were not conducted in foals younger than 2 months of age, or in stallions, the use of the veterinary medicinal product is not recommended in these categories of animals.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after use.

Do not smoke, drink or eat while handling the veterinary medicinal product.  
This veterinary medicinal product may cause skin and eye irritation. Therefore, the user should avoid contact of the veterinary medicinal product with the skin and the eyes. In case of contact, rinse immediately with plenty of water.

In the case of accidental ingestion or eye irritation after contact seek medical advise immediately and show the package insert or the label to the physician.

#### Pregnancy and lactation:

Studies performed in laboratory animals showed no teratogenic or embryotoxic effect of either ivermectin or praziquantel at the recommended doses during therapy.

Ivermectin-Praziquantel combination can be used after the first three months of gestation and during lactation. In the absence of clinical data in early pregnancy the veterinary medicinal product can only be used in the first three months of gestation according to a risk benefit analysis by the veterinarian.

#### Overdose:

No undesirable effects related to treatment were observed in 2-month-old horses treated with the veterinary medicinal product at up to three times the recommended dose and in adult horses treated at ten times the recommended dose.

Transient decreased food consumption, increased body temperature, salivation and impairment of vision were noticed in horses treated twice with an ivermectin oral paste or once with the veterinary medicinal product at ten times the recommended dose (i.e., 2 mg/kg b.w.). All changes disappeared within five days.

No antidote has been identified; however, symptomatic therapy may be beneficial.

## **7. Adverse events**

Horses:

**Rare (1 to 10 animals / 10,000 animals treated):** Oedema<sup>1</sup> and pruritis<sup>1</sup>, inflammation of the mouth, lip and tongue (e.g., oedema, hypersalivation, erythema, tongue disorder and stomatitis)<sup>2</sup>

**Very rare (<1 animal / 10,000 animals treated, including isolated reports):** Colic, loose stool<sup>3</sup>.

<sup>1</sup>Can occur in some horses with heavy infections of *Onchocerca* spp. microfilariae following treatment; such reactions were assumed to be the result of the death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable.

<sup>2</sup>These reactions have been transitory in nature, appearing within 1 hour and abating within 24 to 48 hours following administration. In case of severe oral reactions symptomatic treatment is recommended.

<sup>3</sup>Mild, transient signs may be observed in cases of heavy infestations with tapeworms.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorization holder <or the local representative of the marketing authorization holder> using the contact details at the end of this leaflet, or via your national reporting system at: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine> and [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

Oral use.

The recommended dosage is 200 mcg/kg bw of ivermectin and 1 mg/kg bw of praziquantel corresponding to 1.29 g of paste per 100 kg bodyweight in a single administration.

Bodyweight and dosage should be accurately determined prior to treatment. For syringes intended to treat horses up to 600 kg and 1100 kg, calibrated markings are provided at 100 kg bodyweight intervals. For the syringe intended to treat horses up to 750 kg, calibrated markings are provided at 125 kg bodyweight intervals. The syringe should be adjusted to the calculated dosage by setting the ring on the appropriate place on the plunger.

### Parasite control Program

Veterinary advice should be given on appropriate dosing programs and stock management to achieve adequate parasite control for both tapeworm and roundworm infestations.

## **9. Advice on correct administration**

To ensure a correct dosage, body weight should be determined as accurately as possible.

While holding the plunger, turn the knurled ring on the plunger  $\frac{1}{4}$  turn to the left and slide it so the stop ring is at the prescribed weight marking. Lock the ring in place by turning it  $\frac{1}{4}$  turn to the right in order to bring the two arrows, the one visible on the ring and the one on the plunger rod, into alignment. Make sure the horse's mouth contains no feed. Remove the cover from the tip of the syringe. Insert the syringe tip into the horse's mouth at the interdental space and deposit the paste on the base of the tongue. Immediately raise the horse's head for a few seconds after dosing and ensure that the paste is consumed.

## **10. Withdrawal periods**

Meat and offal: 30 days.

Not authorised for use in animal producing milk for human consumption.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Store in the original container.  
Replace cap after use.  
Shelf life after first opening the immediate packaging: 2 years

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

The veterinary medicinal product should not enter water course as ivermectin and praziquantel may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 08327/5003

### Outer package and sales presentations:

Each syringe is sealed in a transparent polypropylene bag.

Carton box of 1 syringe for oral administration of 7.74g

Carton box of 1 syringe for oral administration of 9.68g

Carton box of 1 syringe for oral administration of 14.19g

Carton box of 50 syringes for oral administration of 7.74g

Carton box of 50 syringes for oral administration of 9.68g

Carton box of 50 syringes for oral administration of 14.19g

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse reaction:

Boehringer Ingelheim Animal Health UK Limited  
Ellesfield Avenue  
Bracknell  
Berkshire  
RG12 8YS  
UK

Manufacturer responsible for batch release:

Boehringer Ingelheim Animal Health France SCS  
4, Chemin du Calquet  
31000 Toulouse  
France

## **17. Other information**

### **Environmental properties**

EXTREMELY DANGEROUS FOR FISH AND AQUATIC LIFE.

POM-VPS

For animal treatment only.

*Gavin Hall*  
Approved: 19 March 2026